Patients with chronic kidney disease and type 2 diabetes receiving pharmacist-led outreach were nearly twice as likely to start an SGLT2 inhibitor as those receiving usual care.

The U.S. SGLT2 Inhibitors Market is projected to grow from USD 5.49 Billion in 2025 to USD 11.06 Billion by 2035, while ...

MADRID — Nearly half of people with type 2 diabetes (T2D) currently recommended to receive sodium-glucose cotransporter 2 (SGLT2) inhibitors for kidney protection would not actually benefit from them, ...

Sodium-glucose cotransporter 2 inhibitors (SGLT2is) may be prescribed to people with heart failure, chronic kidney disease, ...

SGLT2 inhibitors have become a major drug used to treat diabetes, heart failure, and chronic kidney disease. However, there have been questions as to whether it is safe to use these drugs in patients ...

A diabetes drug was linked to a surprising effect on the risk of dementia.

SGLT2 inhibitor use also correlated with lower rates of psychiatric ED visits ...

For patients with diabetes and early-stage pulmonary malignancies, administration of a sodium-glucose cotransporter 2 inhibitor (SGLT2-i) slows nodule growth and reduces the need for surgical ...

New findings add to the pile of research on the possible neuroprotective effects of drugs like dapagliflozin, empagliflozin, and dulaglutide for patients with type 2 diabetes. The primary outcome was ...

The SGLT2 inhibitor empagliflozin confers kidney-protective benefits and can therefore be given safely and effectively to patients when they are hospitalized for acute myocardial infarction (MI), a ...

Patients with SGLT2 inhibitor-associated diabetic ketoacidosis (DKA) received significantly lower doses of insulin in the first 24 hours of treatment compared with patients with type 1 diabetes DKA, ...